Ajanta Pharma Q2 FY27 Revenue Up 33% to ₹1,782 Cr; PAT Rises 49% to ₹388 Cr
Ajanta Pharma reported excellent Q2 FY27 results with revenue up 33% to ₹1,782 crore and PAT up 49% to ₹388 crore. For H1 FY27, revenue grew 29% to ₹3,399 crore and PAT increased 40% to ₹722 crore. The company highlighted strong performance in its branded generics business across key markets and a 41% ROCE.
The substantial increase in revenue and profit, coupled with strong growth across key business segments and markets, is expected to have a significant positive impact on investor sentiment and the company's stock performance.
The company reported significant year-on-year growth in revenue and profit after tax for both the quarter and half-year periods, indicating strong financial performance.
Ajanta Pharma Limited announced its unaudited financial results for the second quarter and half year ended September 30, 2026. The company reported a significant increase in revenue from operations, which stood at ₹1,782 crore for Q2 FY27, a 33% rise compared to ₹1,339 crore in Q2 FY26. Profit after tax (PAT) for the quarter surged by 49% to ₹388 crore, up from ₹260 crore in the same period last year. For the half year ended September 30, 2026, revenue from operations was ₹3,399 crore, a 29% increase from ₹2,628 crore in H1 FY26. PAT for the half year grew by 40% to ₹722 crore from ₹516 crore in H1 FY26. Adjusted EBITDA (excluding forex loss) for Q2 FY27 was ₹543 crore, a 47% increase from ₹369 crore in Q2 FY26. For H1 FY27, Adjusted EBITDA was ₹997 crore, up 34% from ₹745 crore in H1 FY26. The company's ROCE stood at 41% and RONW at 31%. The branded generics business, which forms two-thirds of the company's revenue, showed strong performance across India, Asia, and Africa. The US generics segment also reported robust growth. The company also disclosed its ANDA status with the US FDA and provided details on its R&D expenses, which were ₹72 crore for Q2 FY27 and ₹138 crore for H1 FY27, representing 4% of revenue in both periods. The company will host an Earnings Conference Call on October 30, 2026, at 16:00 IST to discuss its financial performance.
What to do with a filing like this
Ajanta Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Ajanta Pharma Limited. Read the original for the full detail.